An interventional study of Hypofractionated Radiation Therapy and Radiation Therapy in Lung Cancers, sponsored by Chris Goodman. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Chris Goodman · Not applicable, Interventional, and Treatment
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT).
The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 141 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →This is the only study on the registry with Chris Goodman as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
20 Gray in 5 fractions or 30 Gray in 10 fractions.
Radiation: Radiation Therapy
35 Gray in 5 fractions
Radiation: Hypofractionated Radiation Therapy
Hypofractionated, dose-escalated, esophageal-sparing intensity modulated radiation therapy
standard of care palliative thoracic radiotherapy using volumetric modulated arc therapy/intensity-modulating radiotherapy
time to definitive quality of life deterioration or death
Defined as time from randomization to the first of: i. deterioration in Functional Assessment of Cancer Therapy: Lung Trial Outcome Index score by greater than or equal to 5 points compared to baseline score and with no subsequent improvement to within 5 points of baseline ii. death iii. last follow-up
Time frame: from enrollment until 36 months post radiotherapy
Quality of Life - Patient Reported Outcomes
Measured via Functional Assessment of Cancer Therapy: Lung and EuroQol 5-dimension 5-level
Time frame: From enrollment until 36 months post radiotherapy
Toxicity - Adverse Events that happen to a patient during the clinical trial
Defined as incidence of Common Terminology Criteria for Adverse Events version 5 grade 2 and higher toxicity
Time frame: From enrollment until 36 months post radiotherapy
Freedom from intrathoracic progression
Defined as time from randomization to disease progression within the thorax, or last follow-up, whichever occurs first
Time frame: From enrollment until 36 months post radiotherapy
Overall Survival
Defined as time from randomization to death from any cause, or last follow-up, whichever occurs first
Time frame: From enrollment until 36 months post radiotherapy
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.